this says it all
In June 2012, we entered into a sales agreement (the “Sales Agreement”) with an outside placement agent (the “Placement Agent”) to sell shares of our common stock with aggregate gross proceeds of up to $25.0 million from time to time, through an “at-the-market” equity offering program under which the Placement Agent will act as sales agent. As of December 31, 2012 we sold 9,344,611 shares of common stock under the Sales Agreement for net proceeds of $5.3 million. In January and February 2013, we sold 8,222,966 shares of common stock under the Sales Agreement for net proceeds of $5.6 million.
Feel like the latest run up from the .40's to the .80's was a carefully crafted ramp buy the underwriters of the new stock in conjuction with a few new coverages started. You scratch my back I will scratch yours. They got their money, and the bag hold got the shaft. My guess is this thing goes no where fast, my hope is to get back to the .80s
report states hep C phase 2 data is still expected Q1 2013. If they were gonna delay it they would have posted it in the annual report. Also HIV pennvax B phase 1 has a journal preview out for April 2013 edition. If it shows immunogenicity of 90% or higher. Say goodnight to all short sellers and bashers can finally leave my board in peace.